A Randomized Double-blind Placebo-Controlled Phase 2 Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy
Brief description of study
The main purpose of this study is to assess the effectiveness and safety of TAK-341 in adult subjects with multiple system atrophy. Multiple system atrophy is a rare disease of the brain that affects multiple functions of the body, including blood pressure, breathing, urinary function, and various body movements. TAK-341 has been tested in healthy human subjects who received single doses of TAK-341 and was found to be safe and well-tolerated.
Clinical Study Identifier: s22-01037
ClinicalTrials.gov Identifier: NCT05526391
Principal Investigator:
Patricio Alejandro Millar Vernetti.
Other Investigator:
Maria Alejandra Gonzalez-Duarte Briseno.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.